{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:03:33Z","timestamp":1794546213975,"version":"4.9.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","award":["AS-CDA-109-M09"],"award-info":[{"award-number":["AS-CDA-109-M09"]}],"id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Amyotrophic lateral sclerosis (ALS) associated with TAR DNA-binding protein 43 (TDP-43) aggregation has been considered as a lethal and progressive motor neuron disease. Recent studies have shown that both C-terminal TDP-43 (C-TDP-43) aggregates and oligomers were neurotoxic and pathologic agents in ALS and frontotemporal lobar degeneration (FTLD). However, misfolding protein has long been considered as an undruggable target by applying conventional inhibitors, agonists, or antagonists. To provide this unmet medical need, we aim to degrade these misfolding proteins by designing a series of proteolysis targeting chimeras (PROTACs) against C-TDP-43.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>By applying filter trap assay, western blotting, and microscopy imaging, the degradation efficiency of C-TDP-43 aggregates was studied in Neuro-2a cells overexpressing eGFP-C-TDP-43 or mCherry-C-TDP-43. The cell viability was characterized by alarmarBlue assay. The beneficial and disaggregating effects of TDP-43 PROTAC were examined with the YFP-C-TDP-43 transgenic <jats:italic>C. elegans<\/jats:italic> by motility assay and confocal microscopy. The impact of TDP-43 PROTAC on C-TDP-43 oligomeric intermediates was monitored by fluorescence lifetime imaging microscopy and size exclusion chromatography in the Neuro-2a cells co-expressing eGFP-C-TDP-43 and mCherry-C-TDP-43.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four PROTACs with different linker lengths were synthesized and characterized. Among these chimeras, PROTAC <jats:bold>2<\/jats:bold> decreased C-TDP-43 aggregates and relieved C-TDP-43-induced cytotoxicity in Neuro-2a cells without affecting endogenous TDP-43. We showed that PROTAC <jats:bold>2<\/jats:bold> bound to C-TDP-43 aggregates and E3 ligase to initiate ubiquitination and proteolytic degradation. By applying advanced microscopy, it was further shown that PROTAC <jats:bold>2<\/jats:bold> decreased the compactness and population of C-TDP-43 oligomers. In addition to cellular model, PROTAC <jats:bold>2<\/jats:bold> also improved the motility of transgenic <jats:italic>C. elegans<\/jats:italic> by reducing the C-TDP-43 aggregates in the nervous system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study demonstrated the dual-targeting capacity of the newly-designed PROTAC <jats:bold>2<\/jats:bold> against both C-TDP-43 aggregates and oligomers to reduce their neurotoxicity, which shed light on the potential drug development for ALS as well as other neurodegenerative diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12929-023-00921-7","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T08:02:39Z","timestamp":1682496159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera"],"prefix":"10.1186","volume":"30","author":[{"given":"Yu-Ling","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruei-Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-An","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Chen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Jen Rachel","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-7126","authenticated-orcid":false,"given":"Joseph Jen-Tse","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-3408","authenticated-orcid":false,"given":"Jim-Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"921_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-017-0077-5","volume":"6","author":"P Sweeney","year":"2017","unstructured":"Sweeney P, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6.","journal-title":"Transl Neurodegener"},{"key":"921_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565\u201381.","journal-title":"Nat Rev Neurol"},{"key":"921_CR3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1126\/science.1067122","volume":"296","author":"JP Taylor","year":"2002","unstructured":"Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296:1991\u20135.","journal-title":"Science"},{"key":"921_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RNL Lamptey","year":"2022","unstructured":"Lamptey RNL, et al. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23:1851.","journal-title":"Int J Mol Sci"},{"key":"921_CR5","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jconrel.2020.11.021","volume":"330","author":"A Akhtar","year":"2021","unstructured":"Akhtar A, et al. Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics. J Control Release. 2021;330:1152\u201367.","journal-title":"J Control Release"},{"key":"921_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.12.003","volume":"122","author":"KD Onos","year":"2016","unstructured":"Onos KD, Sukoff Rizzo SJ, Howell GR, Sasner M. Toward more predictive genetic mouse models of Alzheimer\u2019s disease. Brain Res Bull. 2016;122:1\u201311.","journal-title":"Brain Res Bull"},{"key":"921_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai AC, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807\u201310.","journal-title":"Angew Chem Int Ed Engl"},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/cr.2016.31","volume":"26","author":"X Huang","year":"2016","unstructured":"Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26:484\u201398.","journal-title":"Cell Res"},{"key":"921_CR9","doi-asserted-by":"publisher","first-page":"11530","DOI":"10.1002\/anie.201706529","volume":"56","author":"S Tomoshige","year":"2017","unstructured":"Tomoshige S, Nomura S, Ohgane K, Hashimoto Y, Ishikawa M. Discovery of small molecules that induce the degradation of huntingtin. Angew Chem Int Ed. 2017;56:11530\u20133.","journal-title":"Angew Chem Int Ed"},{"key":"921_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","volume":"61","author":"I Churcher","year":"2018","unstructured":"Churcher I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J Med Chem. 2018;61:444\u201352.","journal-title":"J Med Chem"},{"key":"921_CR11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/tcr.201800032","volume":"18","author":"Y Itoh","year":"2018","unstructured":"Itoh Y. Chemical protein degradation approach and its application to epigenetic targets. Chem Rec. 2018;18:1681\u2013700.","journal-title":"Chem Rec"},{"key":"921_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cbf.3369","volume":"37","author":"Y Zou","year":"2019","unstructured":"Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem Funct. 2019;37:21\u201330.","journal-title":"Cell Biochem Funct"},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","volume":"4","author":"X Sun","year":"2019","unstructured":"Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64.","journal-title":"Signal Transduct Target Ther"},{"key":"921_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/17460441.2019.1660641","volume":"14","author":"JC Groppe","year":"2019","unstructured":"Groppe JC. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy. Expert Opin Drug Discov. 2019;14:1237\u201353.","journal-title":"Expert Opin Drug Discov"},{"key":"921_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/ph13040074","volume":"13","author":"M Ishikawa","year":"2020","unstructured":"Ishikawa M, Tomoshige S, Demizu Y, Naito M. Selective degradation of target proteins by chimeric small-molecular drugs PROTACs and SNIPERs. Pharmaceuticals (Basel). 2020;13:74.","journal-title":"Pharmaceuticals (Basel)"},{"key":"921_CR16","doi-asserted-by":"publisher","first-page":"112750","DOI":"10.1016\/j.ejmech.2020.112750","volume":"207","author":"D Tomaselli","year":"2020","unstructured":"Tomaselli D, Mautone N, Mai A, Rotili D. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). Eur J Med Chem. 2020;207:112750.","journal-title":"Eur J Med Chem"},{"key":"921_CR17","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/anie.202004746","volume":"60","author":"S Tomoshige","year":"2021","unstructured":"Tomoshige S, Ishikawa M. PROTACs and other chemical protein degradation technologies for the treatment of neurodegenerative disorders. Angew Chem Int Ed Engl. 2021;60:3346\u201354.","journal-title":"Angew Chem Int Ed Engl"},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11:611\u20137.","journal-title":"Nat Chem Biol"},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1146\/annurev.biochem.78.101807.093809","volume":"78","author":"RJ Deshaies","year":"2009","unstructured":"Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399\u2013434.","journal-title":"Annu Rev Biochem"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang X, Feng F, Liu W, Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B. 2020;10:207\u201338.","journal-title":"Acta Pharm Sin B"},{"key":"921_CR21","doi-asserted-by":"publisher","first-page":"11269","DOI":"10.1021\/acs.chemrev.7b00077","volume":"117","author":"GM Burslem","year":"2017","unstructured":"Burslem GM, Crews CM. Small-molecule modulation of protein homeostasis. Chem Rev. 2017;117:11269\u2013301.","journal-title":"Chem Rev"},{"key":"921_CR22","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","volume":"13","author":"C Steinebach","year":"2018","unstructured":"Steinebach C, et al. Homo-PROTACs for the chemical knockdown of cereblon. ACS Chem Biol. 2018;13:2771\u201382.","journal-title":"ACS Chem Biol"},{"key":"921_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/acs.jmedchem.6b01912","volume":"61","author":"KH Chan","year":"2018","unstructured":"Chan KH, Zengerle M, Testa A, Ciulli A. Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds. J Med Chem. 2018;61:504\u201313.","journal-title":"J Med Chem"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1039\/C0MB00074D","volume":"7","author":"K Cyrus","year":"2011","unstructured":"Cyrus K, et al. Impact of linker length on the activity of PROTACs. Mol Biosyst. 2011;7:359\u201364.","journal-title":"Mol Biosyst"},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","volume":"18","author":"AR Schneekloth","year":"2008","unstructured":"Schneekloth AR, Pucheault M, Tae HS, Crews CM. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg Med Chem Lett. 2008;18:5904\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"921_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu J, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015;22:755\u201363.","journal-title":"Chem Biol"},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376\u201381.","journal-title":"Science"},{"key":"921_CR28","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","volume":"61","author":"B Zhou","year":"2018","unstructured":"Zhou B, et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2018;61:462\u201381.","journal-title":"J Med Chem"},{"key":"921_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.chembiol.2016.02.016","volume":"23","author":"TT Chu","year":"2016","unstructured":"Chu TT, et al. Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation. Cell Chem Biol. 2016;23:453\u201361.","journal-title":"Cell Chem Biol"},{"key":"921_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.45457","author":"MC Silva","year":"2019","unstructured":"Silva MC, et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife. 2019. https:\/\/doi.org\/10.7554\/eLife.45457.","journal-title":"Elife"},{"key":"921_CR31","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.4103\/1673-5374.303017","volume":"16","author":"N Tonali","year":"2021","unstructured":"Tonali N, Nencetti S, Orlandini E, Ciccone L. Application of PROTAC strategy to TTR-abeta protein-protein interaction for the development of Alzheimer\u2019s disease drugs. Neural Regen Res. 2021;16:1554\u20135.","journal-title":"Neural Regen Res"},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","volume":"11","author":"RB Kargbo","year":"2020","unstructured":"Kargbo RB. PROTAC compounds targeting alpha-synuclein protein for treating neurogenerative disorders: alzheimer\u2019s and parkinson\u2019s diseases. ACS Med Chem Lett. 2020;11:1086\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"921_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105130","volume":"146","author":"M Montalbano","year":"2020","unstructured":"Montalbano M, et al. TDP-43 and tau oligomers in alzheimer\u2019s disease, amyotrophic lateral sclerosis, and frontotemporal dementia. Neurobiol Dis. 2020;146: 105130.","journal-title":"Neurobiol Dis"},{"key":"921_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40035-021-00250-5","volume":"10","author":"X Xu","year":"2021","unstructured":"Xu X, et al. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Transl Neurodegener. 2021;10:29.","journal-title":"Transl Neurodegener"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130\u20133.","journal-title":"Science"},{"key":"921_CR36","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","volume":"52","author":"M Jo","year":"2020","unstructured":"Jo M, et al. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. 2020;52:1652\u201362.","journal-title":"Exp Mol Med"},{"key":"921_CR37","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.biocel.2010.06.016","volume":"42","author":"ST Warraich","year":"2010","unstructured":"Warraich ST, Yang S, Nicholson GA, Blair IP. TDP-43: a DNA and RNA binding protein with roles in neurodegenerative diseases. Int J Biochem Cell Biol. 2010;42:1606\u20139.","journal-title":"Int J Biochem Cell Biol"},{"key":"921_CR38","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1021\/ja9066207","volume":"132","author":"AK Chen","year":"2010","unstructured":"Chen AK, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132:1186\u20137.","journal-title":"J Am Chem Soc"},{"key":"921_CR39","doi-asserted-by":"publisher","first-page":"18664","DOI":"10.1074\/jbc.M111.231209","volume":"286","author":"Y Furukawa","year":"2011","unstructured":"Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. A seeding reaction recapitulates intracellular formation of sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011;286:18664\u201372.","journal-title":"J Biol Chem"},{"key":"921_CR40","doi-asserted-by":"publisher","first-page":"11212","DOI":"10.1039\/c3cc46762g","volume":"49","author":"GC Liu","year":"2013","unstructured":"Liu GC, et al. Delineating the membrane-disrupting and seeding properties of the TDP-43 amyloidogenic core. Chem Commun (Camb). 2013;49:11212\u20134.","journal-title":"Chem Commun (Camb)"},{"key":"921_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103644","volume":"9","author":"CS Sun","year":"2014","unstructured":"Sun CS, et al. The influence of pathological mutations and proline substitutions in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity. PLoS ONE. 2014;9: e103644.","journal-title":"PLoS ONE"},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1021\/acsnano.7b01645","volume":"11","author":"RY He","year":"2017","unstructured":"He RY, et al. Photocontrollable probe spatiotemporally induces neurotoxic fibrillar aggregates and impairs nucleocytoplasmic trafficking. ACS Nano. 2017;11:6795\u2013807.","journal-title":"ACS Nano"},{"key":"921_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.biochi.2018.05.003","volume":"150","author":"A Prasad","year":"2018","unstructured":"Prasad A, Sivalingam V, Bharathi V, Girdhar A, Patel BK. The amyloidogenicity of a C-terminal region of TDP-43 implicated in amyotrophic lateral sclerosis can be affected by anions, acetylation and homodimerization. Biochimie. 2018;150:76\u201387.","journal-title":"Biochimie"},{"key":"921_CR44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/13506129.2019.1582513","volume":"26","author":"CC Lee","year":"2019","unstructured":"Lee CC, He RY, Huang JJ. Learning from the TDP-43 amyloidogenic sequences in neurodegenerative diseases. Amyloid. 2019;26:154\u20135.","journal-title":"Amyloid"},{"key":"921_CR45","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41467-020-14815-x","volume":"11","author":"K Asakawa","year":"2020","unstructured":"Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat Commun. 2020;11:1004.","journal-title":"Nat Commun"},{"key":"921_CR46","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1038\/ncomms5824","volume":"5","author":"YS Fang","year":"2014","unstructured":"Fang YS, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun. 2014;5:4824.","journal-title":"Nat Commun"},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1039\/c005255h","volume":"6","author":"L Qin","year":"2010","unstructured":"Qin L, Vastl J, Gao J. Highly sensitive amyloid detection enabled by thioflavin T dimers. Mol Biosyst. 2010;6:1791\u20135.","journal-title":"Mol Biosyst"},{"key":"921_CR48","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1002\/chem.201600278","volume":"22","author":"S Ioka","year":"2016","unstructured":"Ioka S, et al. Synthesis of firefly luciferin analogues and evaluation of the luminescent properties. Chemistry. 2016;22:9330\u20137.","journal-title":"Chemistry"},{"key":"921_CR49","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1021\/jm8014525","volume":"52","author":"DS Auld","year":"2009","unstructured":"Auld DS, et al. A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. J Med Chem. 2009;52:1450\u20138.","journal-title":"J Med Chem"},{"key":"921_CR50","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.1039\/c2cp40073a","volume":"14","author":"X Yu","year":"2012","unstructured":"Yu X, et al. Flavin as a photo-active acceptor for efficient energy and charge transfer in a model donor\u2013acceptor system. Phys Chem Chem Phys. 2012;14:6749\u201354.","journal-title":"Phys Chem Chem Phys"},{"key":"921_CR51","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1021\/acschembio.7b00969","volume":"13","author":"M Ishoey","year":"2018","unstructured":"Ishoey M, et al. Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem Biol. 2018;13:553\u201360.","journal-title":"ACS Chem Biol"},{"key":"921_CR52","doi-asserted-by":"publisher","first-page":"1901165","DOI":"10.1002\/advs.201901165","volume":"7","author":"RY He","year":"2020","unstructured":"He RY, et al. Nanoscopic insights of amphiphilic peptide against the oligomer assembly process to treat Huntington\u2019s disease. Adv Sci (Weinh). 2020;7:1901165.","journal-title":"Adv Sci (Weinh)"},{"key":"921_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/1947-2714.128482","volume":"6","author":"ZQ Liu","year":"2014","unstructured":"Liu ZQ, Mahmood T, Yang PC. Western blot: technique, theory and trouble shooting. N Am J Med Sci. 2014;6:160.","journal-title":"N Am J Med Sci"},{"key":"921_CR54","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1093\/hmg\/ddr076","volume":"20","author":"T Zhang","year":"2011","unstructured":"Zhang T, Mullane PC, Periz G, Wang J. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin\/IGF-1 signaling. Hum Mol Genet. 2011;20:1952\u201365.","journal-title":"Hum Mol Genet"},{"key":"921_CR55","doi-asserted-by":"publisher","DOI":"10.3791\/52321","author":"CI Nussbaum-Krammer","year":"2015","unstructured":"Nussbaum-Krammer CI, Neto MF, Brielmann RM, Pedersen JS, Morimoto RI. Investigating the spreading and toxicity of prion-like proteins using the metazoan model organism C. elegans. J Vis Exp. 2015. https:\/\/doi.org\/10.3791\/52321.","journal-title":"J Vis Exp"},{"key":"921_CR56","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/cbic.201100427","volume":"12","author":"A Saini","year":"2011","unstructured":"Saini A, Chauhan VS. Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. ChemBioChem. 2011;12:2495\u2013501.","journal-title":"ChemBioChem"},{"key":"921_CR57","doi-asserted-by":"publisher","first-page":"19614","DOI":"10.1074\/jbc.M113.463828","volume":"288","author":"LL Jiang","year":"2013","unstructured":"Jiang LL, et al. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem. 2013;288:19614\u201324.","journal-title":"J Biol Chem"},{"key":"921_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.abb.2014.01.007","volume":"545","author":"M Mompean","year":"2014","unstructured":"Mompean M, et al. Structural characterization of the minimal segment of TDP-43 competent for aggregation. Arch Biochem Biophys. 2014;545:53\u201362.","journal-title":"Arch Biochem Biophys"},{"key":"921_CR59","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1093\/hmg\/ddu409","volume":"23","author":"L Zhu","year":"2014","unstructured":"Zhu L, et al. An ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel beta-structure and induces TDP-43 redistribution. Hum Mol Genet. 2014;23:6863\u201377.","journal-title":"Hum Mol Genet"},{"key":"921_CR60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fnmol.2018.00372","volume":"11","author":"E Zacco","year":"2018","unstructured":"Zacco E, Martin SR, Thorogate R, Pastore A. The RNA-recognition motifs of TAR DNA-binding protein 43 may play a role in the aberrant self-assembly of the protein. Front Mol Neurosci. 2018;11:372.","journal-title":"Front Mol Neurosci"},{"key":"921_CR61","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2174\/1381612043384772","volume":"10","author":"CA Mathis","year":"2004","unstructured":"Mathis CA, Wang Y, Klunk WE. imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des. 2004;10:1469\u201392.","journal-title":"Curr Pharm Des"},{"key":"921_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jsb.2004.08.002","volume":"149","author":"MR Krebs","year":"2005","unstructured":"Krebs MR, Bromley EH, Donald AM. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol. 2005;149:30\u20137.","journal-title":"J Struct Biol"},{"key":"921_CR63","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.bbapap.2010.04.001","volume":"1804","author":"M Biancalana","year":"2010","unstructured":"Biancalana M, Koide S. Molecular mechanism of thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804:1405\u201312.","journal-title":"Biochim Biophys Acta"},{"key":"921_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2017.1304905","volume":"24","author":"K GadeMalmos","year":"2017","unstructured":"GadeMalmos K, et al. ThT 101: a primer on the use of thioflavin T to investigate amyloid formation. Amyloid. 2017;24:1\u201316.","journal-title":"Amyloid"},{"key":"921_CR65","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","volume":"28","author":"Y Sun","year":"2018","unstructured":"Sun Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018;28:779\u201381.","journal-title":"Cell Res"},{"key":"921_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.37349\/etat.2020.00018","volume":"1","author":"RI Troup","year":"2020","unstructured":"Troup RI, Fallan C, Baud MG. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther. 2020;1:273\u2013312.","journal-title":"Explor Target Antitumor Ther"},{"key":"921_CR67","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.yexcr.2013.05.025","volume":"319","author":"JH Han","year":"2013","unstructured":"Han JH, et al. ALS\/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons. Exp Cell Res. 2013;319:1998\u20132005.","journal-title":"Exp Cell Res"},{"key":"921_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.629326","volume":"9","author":"T Sato","year":"2021","unstructured":"Sato T, Ito T, Handa H. Cereblon-based small-molecule compounds to control neural stem cell proliferation in regenerative medicine. Front Cell Dev Biol. 2021;9: 629326.","journal-title":"Front Cell Dev Biol"},{"key":"921_CR69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-020-00397-1","volume":"15","author":"TR Suk","year":"2020","unstructured":"Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15:45.","journal-title":"Mol Neurodegener"},{"key":"921_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2603","author":"YS Lye","year":"2022","unstructured":"Lye YS, Chen YR. TAR DNA-binding protein 43 oligomers in physiology and pathology. IUBMB Life. 2022. https:\/\/doi.org\/10.1002\/iub.2603.","journal-title":"IUBMB Life"},{"key":"921_CR71","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/cphc.201000996","volume":"12","author":"GS Kaminski Schierle","year":"2011","unstructured":"Kaminski Schierle GS, et al. A FRET sensor for non-invasive imaging of amyloid formation in vivo. ChemPhysChem. 2011;12:673\u201380.","journal-title":"ChemPhysChem"},{"key":"921_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.conb.2015.03.009","volume":"33","author":"M Zhen","year":"2015","unstructured":"Zhen M, Samuel ADC. C. elegans locomotion: small circuits, complex functions. Curr Opin Neurobiol. 2015;33:117\u201326.","journal-title":"Curr Opin Neurobiol"},{"key":"921_CR73","doi-asserted-by":"publisher","first-page":"8371","DOI":"10.1074\/jbc.M111.311977","volume":"287","author":"T Zhang","year":"2012","unstructured":"Zhang T, Hwang HY, Hao H, Talbot C Jr, Wang J. Caenorhabditis elegans RNA-processing protein TDP-1 regulates protein homeostasis and life span. J Biol Chem. 2012;287:8371\u201382.","journal-title":"J Biol Chem"},{"key":"921_CR74","doi-asserted-by":"publisher","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","volume":"115","author":"A Zorba","year":"2018","unstructured":"Zorba A, et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci U S A. 2018;115:E7285\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"921_CR75","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ejmech.2019.05.046","volume":"176","author":"B Wang","year":"2019","unstructured":"Wang B, et al. Development of selective small molecule MDM2 degraders based on nutlin. Eur J Med Chem. 2019;176:476\u201391.","journal-title":"Eur J Med Chem"},{"key":"921_CR76","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","volume":"62","author":"Y Li","year":"2019","unstructured":"Li Y, et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J Med Chem. 2019;62:448\u201366.","journal-title":"J Med Chem"},{"key":"921_CR77","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41422-019-0144-9","volume":"29","author":"J Guo","year":"2019","unstructured":"Guo J, Liu J, Wei W. Degrading proteins in animals: \u201cPROTAC\u201dtion goes in vivo. Cell Res. 2019;29:179\u201380.","journal-title":"Cell Res"},{"key":"921_CR78","first-page":"244","volume":"1","author":"X Han","year":"2022","unstructured":"Han X, Wei W, Sun Y. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Mater Med. 2022;1:244\u201359.","journal-title":"Acta Mater Med"},{"key":"921_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113749","volume":"225","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem. 2021;225: 113749.","journal-title":"Eur J Med Chem"},{"key":"921_CR80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3\u201326.","journal-title":"Adv Drug Deliv Rev"},{"key":"921_CR81","doi-asserted-by":"publisher","first-page":"16930","DOI":"10.1021\/jacs.2c05499","volume":"144","author":"X Liu","year":"2022","unstructured":"Liu X, et al. Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2. J Am Chem Soc. 2022;144:16930\u201352.","journal-title":"J Am Chem Soc"},{"key":"921_CR82","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2:541\u201353.","journal-title":"NeuroRx"},{"key":"921_CR83","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2019.03.004","volume":"127","author":"KM DeMars","year":"2019","unstructured":"DeMars KM, Yang C, Candelario-Jalil E. Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke. Neurochem Int. 2019;127:94\u2013102.","journal-title":"Neurochem Int"},{"key":"921_CR84","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.7150\/thno.55680","volume":"11","author":"W Wang","year":"2021","unstructured":"Wang W, et al. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics. 2021;11:5279\u201395.","journal-title":"Theranostics"},{"key":"921_CR85","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","volume":"79","author":"SC Ling","year":"2013","unstructured":"Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416\u201338.","journal-title":"Neuron"},{"key":"921_CR86","doi-asserted-by":"publisher","first-page":"7789","DOI":"10.1007\/s12035-018-0947-6","volume":"55","author":"E Feneberg","year":"2018","unstructured":"Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018;55:7789\u2013801.","journal-title":"Mol Neurobiol"},{"key":"921_CR87","doi-asserted-by":"publisher","first-page":"8370","DOI":"10.1002\/anie.201713416","volume":"57","author":"J Adamcik","year":"2018","unstructured":"Adamcik J, Mezzenga R. Amyloid polymorphism in the protein folding and aggregation energy landscape. Angew Chem Int Ed Engl. 2018;57:8370\u201382.","journal-title":"Angew Chem Int Ed Engl"},{"key":"921_CR88","doi-asserted-by":"publisher","first-page":"16659","DOI":"10.1038\/s41598-021-96122-z","volume":"11","author":"JA Watkins","year":"2021","unstructured":"Watkins JA, Alix JJP, Shaw PJ, Mead RJ. Extensive phenotypic characterisation of a human TDP-43(Q331K) transgenic mouse model of amyotrophic lateral sclerosis (ALS). Sci Rep. 2021;11:16659.","journal-title":"Sci Rep"},{"key":"921_CR89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40478-020-0881-5","volume":"8","author":"SL Huang","year":"2020","unstructured":"Huang SL, et al. A Robust TDP-43 knock-in mouse model of ALS. Acta \nNeuropathol Commun. 2020;8:3.","journal-title":"Acta Neuropathol Commun"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-023-00921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-023-00921-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-023-00921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T08:08:36Z","timestamp":1682496516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-023-00921-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1186\/s12929-023-00921-7","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}